×
GeoVax Labs EBIT 2010-2025 | GOVX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GeoVax Labs ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
GeoVax Labs EBIT 2010-2025 | GOVX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GeoVax Labs ebit from 2010 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$245.4B
Amgen (AMGN)
$157.5B
Gilead Sciences (GILD)
$146.4B
Vertex Pharmaceuticals (VRTX)
$100B
Bristol Myers Squibb (BMY)
$98.1B
CSL (CSLLY)
$85.5B
GSK (GSK)
$79.6B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$59.9B
Argenex SE (ARGX)
$40.5B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$26.9B
Royalty Pharma (RPRX)
$20.9B
Biogen (BIIB)
$19.9B
Incyte (INCY)
$16.6B
Illumina (ILMN)
$15.5B
Genmab (GNMSF)
$15.3B
Genmab (GMAB)
$15B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11B
Moderna (MRNA)
$10.9B
QIAGEN (QGEN)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.5B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Halozyme Therapeutics (HALO)
$8.1B
Roivant Sciences (ROIV)
$8B